EQT in Talks to Buy Qiagen
Swedish buyout firm EQT is in advanced talks to acquire European molecular testing company Qiagen. EQT has reportedly submitted a binding offer exceeding $50 per share.
Xurve View
Insights:
Xurve View
EQT AB is in advanced talks to acquire QIAGEN N.V. after submitting a binding offer of more than $50 per share, people familiar with the matter said on Tuesday afternoon. The potential buyout values the European molecular testing firm against a market capitalization of €8.57 billion. The discussions follow months of takeover interest from private equity firms seeking to expand in clinical laboratory diagnostics.
